Protein kinase inhibitor

Kinnate Biopharma Closes $98 Million Series C Financing

Retrieved on: 
Wednesday, August 26, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Protein kinase inhibitor, Cancer, Tyrosine kinase receptors, Draft:Sunshine Biopharma, Cancer treatments, Health, Medicine, Life sciences

Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing.

Key Points: 
  • Kinnate Biopharma Inc., a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers, today announced that it has raised $98 million in a Series C financing.
  • In December 2019, Kinnate closed a $74.5 million Series B financing.
  • Kinnate Biopharma Inc. is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically-defined cancers.
  • Headquartered in San Diego, the Kinnate team is composed of drug discovery experts supported by world-class scientific advisors and investors.

Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan

Retrieved on: 
Friday, July 31, 2020
Orphan drugs, Organic compounds, Chemical compounds, Chloroarenes, Ureas, Chemistry, Cyclopropanes, Lenvatinib, Protein kinase inhibitor, Thymic carcinoma

a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate).

Key Points: 
  • a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A., announced today that Eisai has submitted an application in Japan for the additional indication of treatment of unresectable thymic carcinoma for multiple receptor tyrosine kinase inhibitor LENVIMA (generic name: lenvatinib mesylate).
  • In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma.
  • This application is based on the results of an open-label, single-arm, multicenter, investigator-initiated clinical phase II study (NCCH1508) conducted in Japan, evaluating LENVIMA as a single agent in 42 patients with thymic carcinoma previously treated with at least one platinum-based regimen.
  • This study met its endpoint as the lower value of the CI exceeded the pre-specified statistical criteria, a threshold ORR of 10%.

Reverie Labs Enters Multi-target Collaboration Agreement with Roche

Retrieved on: 
Wednesday, July 8, 2020
Companies, Life sciences, Industries, Genentech, Hoffmann-La Roche, South San Francisco, California, Protein kinase inhibitor

CAMBRIDGE, Mass., July 8, 2020 /PRNewswire/ -- Reverie Labs , a pharmaceutical company pioneering the application of artificial intelligence in the discovery and development of next-generation kinase inhibitors, today announced a multi-target collaboration agreement with Roche and Genentech, a member of the Roche Group.

Key Points: 
  • CAMBRIDGE, Mass., July 8, 2020 /PRNewswire/ -- Reverie Labs , a pharmaceutical company pioneering the application of artificial intelligence in the discovery and development of next-generation kinase inhibitors, today announced a multi-target collaboration agreement with Roche and Genentech, a member of the Roche Group.
  • Reverie Labs will use its unique technology platform to perform virtual screening, hit-to-lead generation, and lead optimization on several kinase inhibitor discovery programs, alongside scientists at Roche and Genentech.
  • Reverie Labs will receive an upfront payment and is eligible to receive pre-clinical, clinical, and regulatory milestone payments, as well as tiered royalties on Roche's sales of drug candidates produced by the collaboration.
  • Reverie Labs' unique approach has already led to the discovery of selective, brain-penetrant kinase inhibitors for oncology targets.

Turning Point Therapeutics’ Lead Drug Candidate Repotrectinib Increases Effectiveness of KRAS-G12C and MEK Inhibitors in Preclincal KRAS Cancer Models

Retrieved on: 
Monday, June 22, 2020
RTT, Tyrosine kinase receptors, KRAS, ROS1, Branches of biology, Cancer, Chemical compounds, Non-small-cell lung carcinoma, Carcinogenesis, Ras GTPase, Pancreatic cancer, Protein kinase inhibitor

The repotrectinib-trametinib combination studies were replicated across panels of KRAS mutant non-small cell lung, colorectal and pancreatic cancer cell lines that harbor a spectrum of KRAS mutations.

Key Points: 
  • The repotrectinib-trametinib combination studies were replicated across panels of KRAS mutant non-small cell lung, colorectal and pancreatic cancer cell lines that harbor a spectrum of KRAS mutations.
  • The companys lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Retrieved on: 
Monday, June 22, 2020
Oncology, Health, FDA, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Chemical compounds, Organic compounds, Heterocyclic compounds, Cancer treatments, Pyridines, Imatinib, Piperazines, RTT, Protein kinase inhibitor, Gastrointestinal stromal tumor, Mastocytosis, Sunitinib, the INVICTUS Phase 3 Study, GIST, Deciphera Pharmaceuticals

Health Canadas authorization was based on efficacy results from the pivotal Phase 3 INVICTUS study of QINLOCK in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK.

Key Points: 
  • Health Canadas authorization was based on efficacy results from the pivotal Phase 3 INVICTUS study of QINLOCK in patients with advanced GIST as well as combined safety results from INVICTUS and the Phase 1 study of QINLOCK.
  • Deciphera Pharmaceuticals is developing QINLOCK for the treatment of KIT and/or PDGFR-driven cancers, including GIST, systemic mastocytosis, or SM, and other cancers.
  • QINLOCK (ripretinib) is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
  • Deciphera, Deciphera Pharmaceuticals, QINLOCK, the Deciphera logo and the QINLOCK logo are trademarks of Deciphera Pharmaceuticals, LLC.

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Retrieved on: 
Friday, June 12, 2020
Enzymes, Tyrosine kinases, Branches of biology, CD135, Bruton's tyrosine kinase, Protein kinase inhibitor, Oncogenes, Tyrosine kinase inhibitors

The poster is available on the posters and presentations section of the Aptose website here .

Key Points: 
  • The poster is available on the posters and presentations section of the Aptose website here .
  • CG-806 was well-tolerated in patients treated at 150mg, 300mg and 450mg BID over multiple cycles, with no drug-related dose-limiting toxicities or serious adverse events.
  • The findings also suggest that dose levels evaluated in this study may be therapeutic in patients with AML.
  • CG-806 is an oral, first-in-class FLT3/BTK cluster selective kinase inhibitor and is in Phase 1 clinical studies for the treatment of hematologic malignancies.

BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

Retrieved on: 
Wednesday, June 3, 2020
Organic compounds, Lung cancer, Chemical compounds, Quinazolines, Cancer, Amines, Tyrosine kinase receptors, Erlotinib, Ethers, Non-small-cell lung carcinoma, Protein kinase inhibitor, Epidermal growth factor receptor

Upon reviewing the safety and efficacy data of over 500 patients and approximately 300 pre-specified death events, the Data & Safety Monitoring Board (DSMB) has advised BeyondSpring to continue the study without any modifications.

Key Points: 
  • Upon reviewing the safety and efficacy data of over 500 patients and approximately 300 pre-specified death events, the Data & Safety Monitoring Board (DSMB) has advised BeyondSpring to continue the study without any modifications.
  • EGFR wild-type NSCLC patients make up 85 percent of the NSCLC population; second- / third- line NSCLC with EGFR wild-type represents one of the most significant clinical challenges with limited treatment options.
  • The DSMBs green light is an encouraging step as we continue this trial without modifications following our second interim dataset review.
  • Tyrosine Kinase Inhibitors (TKIs), including Tarceva, are effective for EGFR-mutant, second- / third-line NSCLC patients, with median OS of 18.3 months.

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on: 
Saturday, May 30, 2020
Organic compounds, Chemical compounds, Lung cancer, Quinazolines, Aromatic compounds, Amines, Tyrosine kinase receptors, Tyrosine kinase inhibitors, Erlotinib, Epidermal growth factor receptor, Non-small-cell lung carcinoma, Protein kinase inhibitor

These include several studies investigating CYRAMZA in combination with other anti-cancer therapies for the treatment of multiple tumor types.

Key Points: 
  • These include several studies investigating CYRAMZA in combination with other anti-cancer therapies for the treatment of multiple tumor types.
  • CYRAMZA, in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
  • CYRAMZA, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
  • 10Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046

Retrieved on: 
Friday, May 29, 2020
Oncogenes, Proto-oncogene tyrosine-protein kinase Src, Protein kinase inhibitor

Specifically, in preclinical studies, TPX-0046 inhibited RET solvent front mutations that have been observed in biopsies from patients with progression on a prior RET inhibitor.

Key Points: 
  • Specifically, in preclinical studies, TPX-0046 inhibited RET solvent front mutations that have been observed in biopsies from patients with progression on a prior RET inhibitor.
  • TPX-0046 is a multi-targeted RET and SRC kinase inhibitor with a novel three-dimensional macrocyclic structure that is smaller and structurally distinguished from other approved or investigational RET inhibitors.
  • Dual inhibition of RET and SRC represents a novel therapeutic strategy to target abnormal RET signaling in cancers.
  • Turning Point Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

Retrieved on: 
Monday, May 18, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Johnson & Johnson, Companies, Epidermal growth factor receptor, Janssen Pharmaceutica, Non-small-cell lung carcinoma, Health, Industries, Janssen Biotech, Cilag, KRAS, Protein kinase inhibitor

Janssen Research & Development, LLC, Janssen-Cilag S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Key Points: 
  • Janssen Research & Development, LLC, Janssen-Cilag S.A. and Janssen Biotech, Inc. are part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
  • Amivantamab, an Anti-EGFR-MET Bispecific Antibody, in Patients with EGFR Exon 20 Insertion-Mutated NSCLC.
  • 4 Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer.
  • Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer.